On Jan 08, major Wall Street analysts update their ratings for $Acelyrin (SLRN.US)$, with price targets ranging from $5 to $20.
Morgan Stanley analyst Vikram Purohit maintains with a hold rating, and maintains the target price at $5.
TD Cowen analyst Tyler Van Buren maintains with a buy rating.
Piper Sandler analyst Yasmeen Rahimi maintains with a buy rating, and maintains the target price at $20.
H.C. Wainwright analyst Emily Bodnar maintains with a hold rating, and adjusts the target price from $8 to $6.
Furthermore, according to the comprehensive report, the opinions of $Acelyrin (SLRN.US)$'s main analysts recently are as follows:
Following the presentation of Phase 1b/2 data focusing on dose-finding efficacy and safety in thyroid eye disease for lonigutamab and the introduction of the Phase 3 LONGITUDE program's trial design, the company's stock has faced downward pressure. This is mainly due to the choice of a bi-weekly dosing regimen for Phase 3 and the uncertainties regarding the efficacy expectations for a dose previously untested in the Phase 1b/2 study. Despite seeing value in advancing lonigutamab, the anticipation of no significant catalysts until Phase data is released in the latter half of 2025, coupled with the substantial capital required for two Phase 3 trials and competitive concerns, is expected to continue impacting the stock negatively.
Here are the latest investment ratings and price targets for $Acelyrin (SLRN.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
